{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:29:00Z","timestamp":1793316540616,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"California Institute for Renenerative Medicine","award":["CLIN2-12149"],"award-info":[{"award-number":["CLIN2-12149"]}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Health Small Business Innovation Research"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bneo.2025.100126","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T12:23:43Z","timestamp":1749471823000},"page":"100126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia"],"prefix":"10.1016","volume":"2","author":[{"given":"Ahmed","family":"Aribi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8202-0870","authenticated-orcid":false,"given":"Gabriel N.","family":"Mannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9573-2690","authenticated-orcid":false,"given":"Yazan F.","family":"Madanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4921-5809","authenticated-orcid":false,"given":"Brian A.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8892-0191","authenticated-orcid":false,"given":"Neil","family":"Dunavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-3658","authenticated-orcid":false,"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8822-1814","authenticated-orcid":false,"given":"Deepa","family":"Jeyakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-7807","authenticated-orcid":false,"given":"Hongtao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-3614","authenticated-orcid":false,"given":"Hetty E.","family":"Carraway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0024-9466","authenticated-orcid":false,"given":"Jennifer N.","family":"Saultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0111-7465","authenticated-orcid":false,"given":"William","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7508-3467","authenticated-orcid":false,"given":"Gary","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0077-5554","authenticated-orcid":false,"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2611-9056","authenticated-orcid":false,"given":"Paul","family":"Woodard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-2526","authenticated-orcid":false,"given":"Barbara","family":"Klencke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3446-9192","authenticated-orcid":false,"given":"X. Charlene","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-4283","authenticated-orcid":false,"given":"Hong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6519-4860","authenticated-orcid":false,"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bneo.2025.100126_bib1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100126_bib2","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood.V98.10.2935","article-title":"Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution","volume":"98","author":"N\u00f6sslinger","year":"2001","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bneo.2025.100126_bib3","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood.2023020078","article-title":"Diagnosis and classification of myelodysplastic syndromes","volume":"142","author":"Hasserjian","year":"2023","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bneo.2025.100126_bib4","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100126_bib5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-operative Group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100126_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/16078454.2021.1875600","article-title":"Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review","volume":"26","author":"Xu","year":"2021","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.bneo.2025.100126_bib7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.bneo.2025.100126_bib8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00277-024-05646-7","article-title":"Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study","volume":"103","author":"Zhao","year":"2024","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100126_bib9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41375-024-02466-6","article-title":"Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study","volume":"39","author":"Tremblay","year":"2025","journal-title":"Leukemia"},{"issue":"7728","key":"10.1016\/j.bneo.2025.100126_bib10","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","article-title":"LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration","volume":"562","author":"Deng","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bneo.2025.100126_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cyto.b.21050","article-title":"Expression of immune inhibitor receptor ILT3 in acute myeloid leukemia with monocytic differentiation","volume":"84","author":"Dobrowolska","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"issue":"6","key":"10.1016\/j.bneo.2025.100126_bib12","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1080\/10428194.2020.1723014","article-title":"LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents","volume":"61","author":"Chien","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.bneo.2025.100126_bib13","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","article-title":"A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy","volume":"13","author":"Pei","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.bneo.2025.100126_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","article-title":"Genetic characterization of ABT-199 sensitivity in human AML","volume":"34","author":"Bisaillon","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2025.100126_bib15","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bneo.2025.100126_bib18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2025.100126_bib19","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An International Consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2025.100126_bib20","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.bneo.2025.100126_bib21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2141.2011.08893.x","volume":"155","author":"Van der Helm","year":"2011","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100126_bib22","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3109\/10428194.2012.730615","article-title":"Treatment of chronic myelomonocytic leukemia with azacitidine","volume":"54","author":"Wong","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.bneo.2025.100126_bib23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.leukres.2014.01.006","article-title":"Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival","volume":"38","author":"Pleyer","year":"2014","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.bneo.2025.100126_bib24","first-page":"1142","article-title":"Chronic myelomonocytic leukemia; 2024 update on diagnosis, risk stratification and management","volume":"99","author":"Patnaik","year":"2024","journal-title":"AJH"},{"issue":"10","key":"10.1016\/j.bneo.2025.100126_bib25","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood-2016-07-727800","article-title":"Putting it all together in CMML risk stratification","volume":"128","author":"Steensma","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2025.100126_bib26","first-page":"3650","article-title":"LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma","volume":"109","author":"Gong","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bneo.2025.100126_bib28","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bneo.2025.100126_bib29","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100126_bib30","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood-2024-205451","article-title":"CMML is in the eye of the be_who_lder: interrogating the newly proposed entity of oligomonocytic chronic myelomonocytic leukemia (O-CMML): MDS or CMML?","volume":"144","author":"Komrokji","year":"2024","journal-title":"Blood"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T01:42:28Z","timestamp":1764121348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2950328025000615"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100126","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100126"}}